This Week’s Life Science Headlines

        Litigation
Continue reading...

United States Supreme Court to Determine Whether It Should Hear Lupron Labeling Suit

The United States Supreme Court has been asked to determine whether a drug manufacturer’s older labeling is admissible to establish its failure to warn consumers of a product’s dangerous side effects.  See the Petition for Writ of Certiorari here.   In Klein v. TAP Pharmaceutical, 518 Fed.Appx. 583 (9th Cir. May 14, 2013), the plaintiff alleged a drug manufactured and marketed by TAP Pharmaceuticals, in a joint venture with Abbott Laboratories, did not contain adequate warnings regarding the dangerous side effects associated with Lupron…
Continue reading...

This Week’s Life Science Headlines

        Litigation
Continue reading...